A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder

References

• Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809–16
   PubMed Web of Science ®Google Scholar
• Mulrow CD, Williams Jr JW, Trivedi M, et al. Treatment of depression – newer pharmacotherapies. Psychopharmacol Bull 1998;34:409–579
   PubMed Web of Science ®Google Scholar
• Michaud CM, Murray CJL, Bloom BR. Burden of disease: implications for future research. J Am Med Assoc 2001;285:535–9
   Google Scholar
• Stahl SM. Essential psychopharmacology. Neuroscientific basis and practical applications. Cambridge: Cambridge University Press; 2000
   Google Scholar
• Stahl SM. Basic psychopharmacology of antidepressants. Part 1. Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59\(Suppl 4):5–14
   Google Scholar
• Owen MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305–22
   PubMed Web of Science ®Google Scholar
• Feighner JP. Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psychiatry 1980;41:250–5
   PubMed Web of Science ®Google Scholar
• Fabre LF, Feighner JP. Long-term therapy for depression with trazodone. J Clin Psychiatry 1983;44:17–21
   PubMed Web of Science ®Google Scholar
• Patten SB. The comparative efficacy of trazodone and imipramine in the treatment of depression. Can Med Assoc J 1992;146:1177–82
   Web of Science ®Google Scholar
• Goldberg HL, Finnerty RJ. Trazodone in the treatment of neurotic depression. J Clin Psychiatry 1980;41:430–4
   PubMed Web of Science ®Google Scholar
• Beasley Jr CM, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991;52:294–99
   Google Scholar
• Namiki M, Eiji M, Minemoto H, et al. A clinical phase III study of SME3110 (fluvoxetine maleate) in depressed patients at the Department of internal medicine. A double blind, comparative study with trazodone hydrochloride. J Clin Ther Med 1996;12:651–77
   Google Scholar
• Tsutsui SA, et al. A clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor, in the treatment of depression and depressive state. Jpn Neuropsychopharmacol 1997;19:549–68
   Web of Science ®Google Scholar
• Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998;55:85–120
   Google Scholar
• American Psychiatric Association. DSM-IV diagnostic and statistical manual of mental disorders,4th ed. [International version with ICD-10 codes, 1995]. Washington (DC): American Psychiatric Association;1994
   Google Scholar
• Hamilton M. Development of a rating scale the primary depressive illness. Br J Soc Clin Psychol 1967;6:278–96
   PubMedGoogle Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1997;134:332–89
   Google Scholar
• Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61: 656–63
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment manual for psychopharmacology [revised]. Rockville (MD): US Department of Health, Education and Welfare; 1976. p. 217–222
   Google Scholar
• Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dube EM. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63:577–84
   Google Scholar
• Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60:29–34
   PubMed Web of Science ®Google Scholar
• Perry PJ, Garvey MJ, Kelly MW, Cook BL, Dunner FJ, Winokur G. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psychiatry 1989;50(8):290–4
   PubMed Web of Science ®Google Scholar
• Szegedi A, Wetzel H, Angersbach D, et al. A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry 1997;30:97–105
   PubMed Web of Science ®Google Scholar
• Szegedi A, Wetzel H, Angersbach D, Philipp M, Benkert O. Response to treatment in minor and major depression: results of a double blind comparative study with paroxetine and maprotiline. J Affect Disorders 1997;45:167–78
   Google Scholar
• De Wilde J, Spiers R, Mertens C. A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression. Br J Clin Res 1997;8:23–32
   Google Scholar
• Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double blind randomized trial in major depression. Sleep 1995;18:470–7
   PubMed Web of Science ®Google Scholar
• Saletu-Zyhlarz GM, Abu-Bakr MH, Gruber G, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazo done. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:249–60
   PubMed Web of Science ®Google Scholar
• Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60(Suppl 17):28–31
   PubMed Web of Science ®Google Scholar
• Saletu-Zyhlarz GM, Anderer P, Arnold O, Saletu B. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiology 2003;48:194–208
   Google Scholar
• Pohlmeier H, De Gregorio M, Sieroslawski H. Clinical data on trazodone: a review of the literature. In: Gershon, Rickels, Silvestrini, editors. Trazodone – a new broad spectrum antidepressant [Proc 11th Congress CINP, July 9–14,1978]. Amsterdam: Excerpta Medica; 1980. p. 8–26
   Google Scholar
• Leyman S, Mattelaer PM, Van Steenberge I. Paroxetine: post-marketing experience on 4024 depressed patients in Belgium. Eur J Clin Res 1995;7: 287–96
   Google Scholar